Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva approved for smokers, updates labeling on hepatic failure

Executive Summary

OSI/Genentech's Tarceva (erlotinib) is now indicated for non-small cell lung cancer patients who currently smoke cigarettes, following a Sept. 19 approval. FDA reports that "the submitted data, together with previous findings, indicate that smoking reduces erlotinib exposure in both cancer patients and healthy volunteers." The agency notes that the optimal dose adjustment to compensate for this alteration is not known. Labeling is also updated Sept. 23 after cases of hepatic failure and hepatorenal syndrome, including fatalities, were reported. New data are added from a pharmacokinetic study in patients with moderate hepatic impairment associated with significant liver tumor burden, along with statements in Warnings and Dosage and Administration sections
UsernamePublicRestriction

Register

PS050160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel